Reporter covering health and medicine Education: Syracuse University, BS in journalism Laurie McGinley covers health and medicine for The Washington Post. She focuses on the Food and Drug Administration as well as cancer research and treatment. She was previously The Post's health, science and environment editor. Honors & Awards:
Part of Wall Street Journal team that won the 1997 Pulitzer Prize for national reporting on AIDS
Professional Affiliations: Association of Health Care Journalists
Pfizer filed for emergency authorization for its coronavirus vaccine Friday, capping a two-week period marked by blockbuster scientific advances against the pandemic but also its ghastly toll: an additional 1.5 millon people diagnosed with covid-19, the disease caused by the virus, and 13,000 deaths.
President Trump is lashing out at the Food and Drug Administration following a disclosure Monday that an experimental coronavirus vaccine from pharmaceutical giant Pfizer is more than 90 percent effective, convinced the timing — six days after Election Day — proves the “medical deep state” deliberately tried to sabotage his electoral prospects by delaying the results.
The news Monday that Pfizer’s coronavirus vaccine is more than 90 percent effective sharply increased prospects that federal regulators will authorize the vaccine on an emergency basis as early as mid-December, and that the first shots will be administered before the end of the year or early next year.
An experimental Alzheimer’s disease drug described by FDA staff as safe and effective stumbled badly when an agency advisory committee said there was not sufficient evidence to conclude the drug is effective. The non-binding action raised questions about whether the FDA would approve the drug.